Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 25, 2003. The report details specific corporate actions regarding share repurchases and changes in directors' interests rather than providing comprehensive financial results for a fiscal quarter.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to a specific share transaction:
- Share Repurchase Price: 1,283.31 pence per share.
- Shares Purchased for Cancellation: 778,000 Ordinary 25 pence shares.
Material Changes
The primary material event reported is the execution of a share buyback program authorized by shareholders at the Annual General Meeting on May 19, 2003. On September 23, 2003, the company purchased 778,000 shares for cancellation. Additionally, the GSK Trust transferred 33,692 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report of a completed transaction and a disclosure of director interests.
Investor Verification Checklist
- Verify the total number of shares repurchased under the May 2003 authorization to date.
- Confirm the impact of the 778,000 share cancellation on the company's total share count.
- Review the full details of the SmithKline Beecham Employee Share Option Plan 1991 regarding the 33,692 shares transferred.
- Check subsequent filings for the next scheduled financial results, as this document does not contain them.